1. Academic Validation
  2. Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions

Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions

  • Nat Chem. 2020 Oct;12(10):952-961. doi: 10.1038/s41557-020-0514-4.
Hafeez S Haniff 1 Laurent Knerr 2 Xiaohui Liu 1 Gogce Crynen 3 Jonas Boström 2 Daniel Abegg 1 Alexander Adibekian 1 Elizabeth Lekah 1 Kye Won Wang 4 Michael D Cameron 5 Ilyas Yildirim 4 Malin Lemurell 2 Matthew D Disney 6
Affiliations

Affiliations

  • 1 Department of Chemistry, The Scripps Research Institute, Jupiter, FL, USA.
  • 2 Department of Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • 3 Informatic Core, The Scripps Research Institute, Jupiter, FL, USA.
  • 4 Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, FL, USA.
  • 5 Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA.
  • 6 Department of Chemistry, The Scripps Research Institute, Jupiter, FL, USA. disney@scripps.edu.
Abstract

Vascular endothelial growth factor A (VEGFA) stimulates angiogenesis in human endothelial cells, and increasing its expression is a potential treatment for heart failure. Here, we report the design of a small molecule (TGP-377) that specifically and potently enhances VEGFA expression by the targeting of a non-coding MicroRNA that regulates its expression. A selection-based screen, named two-dimensional combinatorial screening, revealed preferences in small-molecule chemotypes that bind RNA and preferences in the RNA motifs that bind small molecules. The screening program increased the dataset of known RNA motif-small molecule binding partners by 20-fold. Analysis of this dataset against the RNA-mediated pathways that regulate VEGFA defined that the microRNA-377 precursor, which represses Vegfa messenger RNA translation, is druggable in a selective manner. We designed TGP-377 to potently and specifically upregulate VEGFA in human umbilical vein endothelial cells. These studies illustrate the power of two-dimensional combinatorial screening to define molecular recognition events between 'undruggable' biomolecules and small molecules, and the ability of sequence-based design to deliver efficacious structure-specific compounds.

Figures
Products